Literature DB >> 17051621

Designer T cells by T cell receptor replacement.

Daniel Sommermeyer1, Julia Neudorfer, Monika Weinhold, Matthias Leisegang, Boris Engels, Elfriede Noessner, Mirjam H M Heemskerk, Jehad Charo, Dolores J Schendel, Thomas Blankenstein, Helga Bernhard, Wolfgang Uckert.   

Abstract

T cell receptor (TCR) gene transfer is a convenient method to produce antigen-specific T cells for adoptive therapy. However, the expression of two TCR in T cells could impair their function or cause unwanted effects by mixed TCR heterodimers. With five different TCR and four different T cells, either mouse or human, we show that some TCR are strong--in terms of cell surface expression--and replace weak TCR on the cell surface, resulting in exchange of antigen specificity. Two strong TCR are co-expressed. A mouse TCR replaces human TCR on human T cells. Even though it is still poorly understood why some TCRalpha/beta combinations are preferentially expressed on T cells, our data suggest that, in the future, designer T cells with exclusive tumor reactivity can be generated by T cell engineering.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17051621     DOI: 10.1002/eji.200636539

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  34 in total

1.  Genetic engineering of murine CD8+ and CD4+ T cells for preclinical adoptive immunotherapy studies.

Authors:  Sid P Kerkar; Luis Sanchez-Perez; Shicheng Yang; Zachary A Borman; Pawel Muranski; Yun Ji; Dhanalakshmi Chinnasamy; Andrew D M Kaiser; Christian S Hinrichs; Christopher A Klebanoff; Christopher D Scott; Luca Gattinoni; Richard A Morgan; Steven A Rosenberg; Nicholas P Restifo
Journal:  J Immunother       Date:  2011-05       Impact factor: 4.456

2.  Single-chain VαVβ T-cell receptors function without mispairing with endogenous TCR chains.

Authors:  D H Aggen; A S Chervin; T M Schmitt; B Engels; J D Stone; S A Richman; K H Piepenbrink; B M Baker; P D Greenberg; H Schreiber; D M Kranz
Journal:  Gene Ther       Date:  2011-07-14       Impact factor: 5.250

Review 3.  Applications of molecular engineering in T-cell-based immunotherapies.

Authors:  David A McBride; Matthew D Kerr; Shinya L Wai; Nisarg J Shah
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2019-04-10

4.  RNAi-mediated TCR knockdown prevents autoimmunity in mice caused by mixed TCR dimers following TCR gene transfer.

Authors:  Mario Bunse; Gavin M Bendle; Carsten Linnemann; Laura Bies; Stephan Schulz; Ton N Schumacher; Wolfgang Uckert
Journal:  Mol Ther       Date:  2014-07-22       Impact factor: 11.454

Review 5.  NCI First International Workshop on The Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic malignancies.

Authors:  Edwin P Alyea; Daniel J DeAngelo; Jeffrey Moldrem; John M Pagel; Donna Przepiorka; Michel Sadelin; James W Young; Sergio Giralt; Michael Bishop; Stan Riddell
Journal:  Biol Blood Marrow Transplant       Date:  2010-05-24       Impact factor: 5.742

6.  Influenza virus-specific TCR-transduced T cells as a model for adoptive immunotherapy.

Authors:  Belinda Berdien; Henrike Reinhard; Sabrina Meyer; Stefanie Spöck; Nicolaus Kröger; Djordje Atanackovic; Boris Fehse
Journal:  Hum Vaccin Immunother       Date:  2013-02-21       Impact factor: 3.452

7.  T-cell receptor gene therapy of established tumors in a murine melanoma model.

Authors:  John D Abad; Claudia Wrzensinski; Willem Overwijk; Moniek A De Witte; Annelies Jorritsma; Cary Hsu; Luca Gattinoni; Cyrille J Cohen; Chrystal M Paulos; Douglas C Palmer; John B A G Haanen; Ton N M Schumacher; Steven A Rosenberg; Nicholas P Restifo; Richard A Morgan
Journal:  J Immunother       Date:  2008-01       Impact factor: 4.456

8.  Targeting B-cell neoplasia with T-cell receptors recognizing a CD20-derived peptide on patient-specific HLA.

Authors:  Nadia Mensali; Fan Ying; Vincent Oei Yi Sheng; Weiwen Yang; Even Walseng; Shraddha Kumari; Lars-Egil Fallang; Arne Kolstad; Wolfgang Uckert; Karl Johan Malmberg; Sébastien Wälchli; Johanna Olweus
Journal:  Oncoimmunology       Date:  2016-02-18       Impact factor: 8.110

Review 9.  Harnessing innate and adaptive immunity for adoptive cell therapy of renal cell carcinoma.

Authors:  Christiane Geiger; Elfriede Nössner; Bernhard Frankenberger; Christine S Falk; Heike Pohla; Dolores J Schendel
Journal:  J Mol Med (Berl)       Date:  2009-03-07       Impact factor: 4.599

Review 10.  T cell receptor gene therapy for cancer.

Authors:  Thomas M Schmitt; Gunnar B Ragnarsson; Philip D Greenberg
Journal:  Hum Gene Ther       Date:  2009-11       Impact factor: 5.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.